Avaliação do tratamento da cromoblastomicose experimental utilizando vacina de DNA (DNA-hsp65)
AUTOR(ES)
Isaque Medeiros Siqueira
DATA DE PUBLICAÇÃO
2010
RESUMO
Chromoblastomycosis (CBM) is a chronic worldwide subcutaneous mycosis, caused by several dimorphic, pigmented dematiaceous fungi. Patients with the disease are still considered as therapeutic challenge, mainly due to its recalcitrant nature. There is no treatment of choice for this neglected mycosis, but rather several treatment options. Itraconazole and terbinafine showed the best results in treating the disease, although the healing of severe cases is still uncommon. However, several studies have reported the DNA vaccine as promising in the treatment of fungal infections, which allow the host to restore depressed cellular immunity, minimizing the toxic effects from conventional antifungal therapies. In this matter, this work was conducted aiming the establishment of a suitable model for experimental CBM, suggesting also new therapies, including DNA-hsp65 vaccine. By analyzing the morfometrical and histopathological aspects, also the recovery/quantification of colony forming units, the results showed the establishment of a chronic, although transitory, experimental CBM model with lesions similar to that presented in humans. The treatment regimen using itraconazole and amphotericin B, intralesionally, was effective in treating experimental CBM, as well as therapy using naked DNA-hsp65 vaccine. It also has been shown that chemotherapy associated with DNA-hsp65 vaccine is efficient in the treatment of experimental CBM, accelerating the healing process of the disease, becoming able to tone down the toxic effects from prolonged chemotherapy.
ASSUNTO(S)
modelo experimental imunologia aplicada cromoblastomicose amphotericin b itraconazol anfotericina b dna-hsp65 itraconazole dna vaccine dna-hsp65 experimental model vacina de dna chromoblastomycosis
Documentos Relacionados
- Influência do biofármaco DNA-hsp65 na lesão pulmonar induzida por bleomicina
- Th1 polarized response induced by intramuscular DNA-HSP65 immunization is preserved in experimental atherosclerosis
- Vacina de DNA (hsp65 M. Leprae) para Paracoccidioidomicose Experimental: atividade imunogênica e terapêutica
- Comparison of BCG and different delivery systems of DNAhsp65 vaccine for the induction of protection against tuberculosis in guinea pigs
- B cells expressing IL-10 mRNA modulate memory T cells after DNA-Hsp65 immunization